Clinical Trial Update: HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating hepatic arterial infusion chemotherapy (HAIC) combined with TQB2450 and Anlotinib for second-line treatment of advanced hepatocellular …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• TQB2450

Snippet

Sponsor: Fudan University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING